isavuconazonium sulfate

Isavuconazonium is prescribed for the treatment of severe fungal infections, including invasive aspergillosis and invasive mucormycosis. These infections typically originate in the lungs, sinuses, brain, or other organs and can spread through the bloodstream.

Isavuconazole, a newly developed extended-spectrum triazole, demonstrates efficacy against a wide range of fungal infections including yeasts, molds, and dimorphic fungi. It has been granted approval for the treatment of invasive aspergillosis and mucormycosis.

Antifungal medication, specifically CRESEMBA® (isavuconazonium sulfate), is prescribed.

The median duration of treatment with isavuconazole was 81 days, with an interquartile range of 15-197. Out of the total patients, two (3.8%) experienced breakthrough fungal infections. One patient had Aspergillus fumigatus infection, which was confirmed to be susceptible to azoles. The other patient had a Scopulariopsis sp. infection with an isavuconazole minimum inhibitory concentration (MIC) greater than 8 ?¼g/mL. Additionally, 49.1% of the patients experienced at least one adverse event.

The interpretation of the study results shows that Isavuconazole was found to be just as effective as voriconazole in treating suspected invasive mould disease. Additionally, Isavuconazole was better tolerated by patients compared to voriconazole, as there were fewer adverse events related to the study drug.

For adult patients weighing less than 40 kg, the oral maintenance dose should be reduced by half. In a clinical trial of IA, the median duration of intravenous VFEND therapy was 10 days, with a range of 2 to 85 days.

Isavuconazole, a triazole antifungal, has a wide range of effectiveness and is considered safe 1. It has been approved by the FDA and EMA for treating invasive aspergillosis and mucormycosis. Its mechanism of action involves inhibiting the synthesis of fungal cell membranes.

Isavuconazole is administered either orally or intravenously in the form of a water-soluble prodrug called isavuconazonium.

Isavuconazole is a wide-ranging antifungal medication that has a similar in vitro activity profile to voriconazole against yeasts, dimorphic fungi, and molds (Table 1). However, it also has the added benefit of being effective against the members of the order Mucorales, which are the causative agents of mucormycosis (16).

Cresemba, also known as isavuconazonium sulfate, is a triazole-class systemic antifungal medication. It is prescribed for the treatment of invasive aspergillosis and mucormycosis.

CRESEMBA, also known as isavuconazonium sulfate, is a prodrug of isavuconazole, which is an antifungal drug belonging to the azole class.

Cresemba (isavuconazonium sulfate) functions by blocking the production of ergosterol, a crucial element in the fungal cell membrane. This is achieved through the inhibition of lanosterol 14-alpha-demethylase, a cytochrome P-450-dependent enzyme.

If you experience confusion, fatigue, drowsiness, or fainting while taking CRESEMBA, refrain from driving or operating machinery. Notify your doctor promptly if you develop severe blistering on your skin, mouth, eyes, or genitals.

In case of a compromised immune system or a challenging infection, the duration of CRESEMBA treatment may exceed 6 months. Your physician may transition you from CRESEMBA IV Injection to CRESEMBA Capsules upon improvement of your condition. It is important to adhere to your doctor’s instructions and continue taking CRESEMBA for the recommended duration.

The combination of ampicillin and sulbactam exhibits synergy, allowing it to effectively target bacteria strains that are resistant to ampicillin. This broader coverage is achieved by its susceptibility to Haemophilus influenzae, Escherichia coli, Acinetobacter, Klebsiella, Staphylococcus aureus, Enterobacter, and anaerobes.

Ampicillin and sulbactam combination is an antibiotic classified as a penicillin and beta-lactamase inhibitor. Its mechanism of action involves killing bacteria and inhibiting their growth. It is important to note that this medication is ineffective against colds, flu, and other viral infections.

Isavuconazole, a triazole, has previously demonstrated strong in vitro activity against Aspergillus spp., Mucorales, and Candida spp.

On March 6, 2015, Astellas was granted FDA approval for the use of CRESEMBA® (isavuconazonium sulfate) in treating invasive Aspergillosis and invasive Mucormycosis.

Overall, isavuconazole has a favorable side effect profile compared to other drugs in the azole class and is generally well tolerated. The most frequently reported side effects are nausea, vomiting, and diarrhea.

Following its approval by the US Food and Drug Administration, isavuconazole has become a primary treatment for IA and mucormycosis mold infections. Additionally, the European Medicines Agency has approved its use in cases where amphotericin B is not the most suitable option.

CRESEMBA is a type of antifungal medication called an azole. It is used to treat two types of fungal infections called invasive aspergillosis and invasive mucormycosis. This medication is only approved for patients who are 18 years of age or older.

Isavuconazonium sulfate undergoes metabolism primarily by serum butylcholinesterase to form isavuconazole. Isavuconazole is then metabolized in the liver by the enzymes CYP3A4 and CYP3A5, as well as uridine diphosphate-glucuronosyl transferase, resulting in the formation of inactive metabolites.

Table 1: Prescription Guidelines for CRESEMBA (isavuconazonium sulfate)

– CRESEMBA is a prodrug of isavuconazole, an azole antifungal drug.
– Both intravenous and oral formulations of CRESEMBA are available.
– Switching between the intravenous and oral formulations is acceptable as bioequivalence has been demonstrated.

Please follow the guidelines below when prescribing CRESEMBA:

1. Dosage:
– The recommended dosage for invasive aspergillosis and invasive mucormycosis is 372 mg (equivalent to 200 mg of isavuconazole) administered intravenously every 8 hours for the first 48 hours, followed by 372 mg (equivalent to 200 mg of isavuconazole) administered intravenously once daily.
– After at least 6 days of intravenous therapy, switch to the oral formulation of CRESEMBA at a dosage of 372 mg (equivalent to 200 mg of isavuconazole) once daily.

2. Administration:
– For intravenous administration, reconstitute the vial with 19 mL of 0.9% Sodium Chloride Injection, USP, and further dilute the reconstituted solution in 250 mL of 0.9% Sodium Chloride Injection, USP. Infuse the diluted solution over 1 hour.
– For oral administration, take CRESEMBA capsules with food.

3. Monitoring:
– Monitor liver function tests (ALT, AST, and total bilirubin) before initiation of therapy and regularly during treatment.
– Monitor renal function (serum creatinine and estimated creatinine clearance) before initiation of therapy and during treatment.

4. Drug Interactions:
– CRESEMBA may interact with other drugs, including strong CYP3A4 inhibitors and inducers. Please refer to the prescribing information for a complete list of potential drug interactions.

5. Adverse Reactions:
– The most common adverse reactions (10%) reported in clinical trials include nausea, vomiting, diarrhea, headache, and abnormal liver function tests.

Please consult the prescribing information for complete dosage and administration instructions, as well as important safety information.

Cresemba, also known as isavuconazonium sulfate, is a triazole-class systemic antifungal medication. It is prescribed for the treatment of invasive aspergillosis and mucormycosis.

Isavuconazonium Sulfate is a sulfate ester form of isavuconazonium, which is a prodrug of isavuconazole, a triazole antifungal agent with a wide range of antifungal activity. When administered, isavuconazonium sulfate is broken down by plasma esterases to produce the active component, isavuconazole.

Cresemba, which is classified as an azole antifungal agent, received FDA approval on March 6, 2015.

Cresemba (isavuconazonium) belongs to the azole antifungals drug class and is frequently prescribed for the treatment of Aspergillosis – Invasive and Mucormycosis – Invasive. The price of Cresemba intravenous powder for injection 372 mg is approximately $3,849 for a 10-powder supply, varying depending on the pharmacy you choose.

Isavuconazole, a newly developed extended-spectrum triazole, demonstrates efficacy against a wide range of fungal infections including yeasts, molds, and dimorphic fungi. It has been granted approval for the treatment of invasive aspergillosis and mucormycosis.

Previous studies in healthy individuals have demonstrated that isavuconazole has a volume of distribution ranging from 308.0 to 542.0 liters, a total systemic clearance (CL) of 2.4 to 4.1 liters/h, almost complete bioavailability, and a half-life of 84.5 to 117.0 hours (7).

Catalogue number: PA 09 42510
Molecular form: C35H36F2N8O9S2
Appearance: NA
Mol. Weight: 814.84
Storage: 2-8°C Refrigerator

Vfend (voriconazole) is a medication that is used to treat infections caused by yeast or other types of fungus. It is an antifungal medication.

CRESEMBA is a medication that contains isavuconazole as its active ingredient. It is prescribed for the treatment of fungal infections, specifically invasive aspergillosis and invasive mucormycosis.

Isavuconazonium sulfate is the prodrug of isavuconazole, which is the active moiety. Therefore, the term “isavuconazole” will be used throughout this review, except where noted. In vitro, isavuconazole has a broad spectrum of activity against yeasts, dimorphic fungi, and molds, particularly Aspergillus spp. and Mucormycetes.